The Company will be focusing on the following programs with Bucillamine: Revive is targeting nerve agent exposure as its initial indication for its medical countermeasures program. Nerve agents are ...
A few companies are in clinicals with novel approaches to heal an initial brain injury or minimize secondary damage. Slow progress may be more related to investors’ misperceptions of the topic than ...